Literature DB >> 16280759

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer.

Claudio Teloken1, Carlos Teodósio Da Ros, Fernanda Caraver, Fernanda A Weber, Ana P Cavalheiro, Tulio Meyer Graziottin.   

Abstract

PURPOSE: It has been reported that more aggressive prostate cancer (PC) can be associated with low serum testosterone levels. The relationship between serum androgens and PC is still not completely understood. In this study we examined the association of prognostic factors in men who underwent radical retropubic (RRP) prostatectomy with low or normal total testosterone.
MATERIALS AND METHODS: We retrospectively evaluated 64 consecutive patients with localized PC treated with RRP between July 2002 and November 2003. PC was diagnosed by transrectal ultrasonography guided biopsy performed for either a suspicious digital rectal examination or serum prostate specific antigen greater than 4.0 ng/ml. Gleason score was determined in prostatic biopsies. Pathological TNM staging (1997), capsular perforation, seminal vesicle involvement and surgical margin status were determined in all surgical specimens. The threshold for serum total testosterone was 270 ng/dl. In all analyses p <0.05 was considered statistically significant.
RESULTS: There were no statistically significant differences among prostate specific antigen, Gleason score (biopsy or specimen), pathological stage, capsular perforation and seminal vesicle involvement. However, patients with low total testosterone had increased positive surgical margins (p = 0.026).
CONCLUSIONS: Patients with low total testosterone more frequently present with positive surgical margins in RRP specimens. The true association between low testosterone and poor clinical outcome in the long term needs validation in large prospective studies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280759     DOI: 10.1097/01.ju.0000181818.51977.29

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  30 in total

1.  Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy.

Authors:  Andrea Salonia; Andrea Gallina; Firas Abdollah; Alberto Briganti; Umberto Capitanio; Nazareno Suardi; Matteo Ferrari; Marco Raber; Renzo Colombo; Massimo Freschi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2011-09-21       Impact factor: 4.226

2.  Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.

Authors:  Eduard García-Cruz; Jorge Huguet; Marta Piqueras; Meritxell Pérez Márquez; Lluís Peri; Laura Izquierdo; Agustín Franco; Ricardo Alvarez-Vijande; María José Ribal; Antonio Alcaraz
Journal:  World J Urol       Date:  2011-08-11       Impact factor: 4.226

Review 3.  The safety of testosterone supplementation therapy in prostate cancer.

Authors:  James M Dupree; Gavin M Langille; Mohit Khera; Larry I Lipshultz
Journal:  Nat Rev Urol       Date:  2014-07-29       Impact factor: 14.432

Review 4.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

5.  Significance of Serum Testosterone for Prostate-Specific Antigen (PSA) Elevation and Prediction of Prostate Cancer in Patients with PSA Above 10 ng/ml.

Authors:  Jin Mo Koo; Bong Suk Shim
Journal:  Korean J Urol       Date:  2010-12-21

6.  Metabolic syndrome and urologic diseases.

Authors:  Ilya Gorbachinsky; Haluk Akpinar; Dean G Assimos
Journal:  Rev Urol       Date:  2010

Review 7.  Testosterone deficiency and replacement: Myths and realities.

Authors:  Ethan D Grober
Journal:  Can Urol Assoc J       Date:  2014-07       Impact factor: 1.862

Review 8.  Testosterone Therapy Among Prostate Cancer Survivors.

Authors:  Taylor M Nguyen; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-07-27

9.  Preoperative low serum testosterone is associated with high-grade prostate cancer and an increased Gleason score upgrading.

Authors:  A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-10-06       Impact factor: 5.554

10.  Low free and bioavailable testosterone levels may predict pathologically-proven high-risk prostate cancer: a prospective, clinical trial.

Authors:  Göksel Bayar; Hakan Şirin; Mustafa Aydın; Ayşim Özağarı; Orhan Tanrıverdi; Mustafa Kadıhasanoğlu; Muammer Kendirci
Journal:  Turk J Urol       Date:  2017-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.